StockWatch
·
Pharmaceuticals
Quarterly Result12 Nov 2026, 07:04 pm

Kerala Ayurveda Q2 FY27: Operating EBITDA Losses Narrow by ₹1.05 Cr

AI Summary

Kerala Ayurveda Ltd (KAL) announced a turnaround in Q2 FY27, with sequential operating EBITDA losses narrowing by ₹1.05 Crores (370 bps) and sequential operating revenue growing by 7.7%. For H1 FY27, revenue from operations grew 8.7% to ₹68.9 Crores. Adjusted EBITDA losses for H1 FY27 narrowed by ₹3.9 Crores. The company attributes these improvements to tighter cost controls and margin efficiencies, which have offset macro-economic headwinds. KAL is on track to achieve Adjusted EBITDA breakeven by Q3 FY27. Despite challenges like Middle East tensions affecting wellness retreats and US economic conditions impacting academy enrollments, KAL is expanding its Global Health Services footprint with new clinics and resorts planned. The company aims to close FY27 with ₹150 Crores in revenue and halve its full-year adjusted EBITDA losses, reiterating its Vision 2030 ambition to reach ₹1,000 Crores in revenue by FY30.

Key Highlights

  • Q2 FY27 operating EBITDA losses narrowed sequentially by ₹1.05 Crores.
  • H1 FY27 revenue grew 8.7% to ₹68.9 Crores, with Adjusted EBITDA losses narrowing.
  • Cost controls and margin efficiencies are driving improvements.
  • Company on track for Adjusted EBITDA breakeven by Q3 FY27.
  • Expansion plans include new clinics and resorts globally.